1
|
Schulz S, Cankaya R, Walter F, Moritz R, Schlaak M, Eigentler T, Dobos G. Time to next treatment in early-stage mycosis fungoides: a retrospective study from the Charité cutaneous lymphoma registry. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00655-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Berking C, Livingstone E, Weichenthal M, Leiter-Stoppke U, Remy J, Eigentler T, Mohr P, Kiecker F, Loquai C, Debus D, Gutzmer R. 828P Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Becker J, Ugurel S, Leiter-Stoppke U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler T, Hauschild A, Kiecker F, Hassel J, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Eckhardt S, Schadendorf D. 787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Cankaya R, Schulz S, Moritz R, Walter F, Schlaak M, Eigentler T, Dobos G. Skin directed therapy superior to systemic treatment in primary cutaneous B-cell lymphoma? A study from the Charité cutaneous lymphoma registry on time to next treatment. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00654-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Eigentler T. Benefits of a nationwide population-based skin cancer screening programme - still a controversial debate. Br J Dermatol 2021; 186:8-9. [PMID: 34605008 DOI: 10.1111/bjd.20709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 07/22/2021] [Indexed: 11/27/2022]
Affiliation(s)
- T Eigentler
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Luisenstrasse 2, Berlin, 10177, Germany
| |
Collapse
|
6
|
Gutzmer R, Eigentler T, Mohr P, Weichenthal M, Dücker P, Gebhardt C, Göppner D, Grimmelmann I, Haferkamp S, Kähler K, Meier F, Pföhler C, Sickmann T, Sindrilaru A, Terheyden P, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D. 1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Chatziioannou E, Rossner J, Niessner H, Forchhammer S, Bonzheim I, Garbe C, Flatz L, Eigentler T, Aung T, Rimm D, Sinnberg T, Amaral T. 1055P Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
8
|
Amaral T, Nolinski J, Niessner H, Sinnberg T, Seeber O, Sanchez S, Keim U, Thomas I, Meiwes A, Koechel A, Forschner A, Leiter U, Flatz L, Eigentler T, Garbe C. 1044P Sequential targeted and immunotherapies in stage IV melanoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Rischin D, Hughes B, Basset-Séguin N, Schadendorf D, Bowyer S, Trabelsi S, Meier F, Eigentler T, Casado Echarren V, Migden M, Hauschild A, Schmults C, Yoo SY, Paccaly A, Jankovic V, Seebach F, Drutman S, Booth J, Fury M, Guminski A. 1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Philipp-Dormston WG, Aschoff R, von Braunmühl T, Eigentler T, Haalck T, Thoms KM. [Decision criteria and patient characteristics for patient-oriented treatment of field cancerization : Standardized algorithm for personalized treatment concepts]. Hautarzt 2021; 72:314-320. [PMID: 33263779 PMCID: PMC8016782 DOI: 10.1007/s00105-020-04731-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Hintergrund Aktinische Keratosen (AK) zeichnen sich durch einen chronischen Verlauf aus, und häufig ist ein ganzes Hautareal betroffen (Feldkanzerisierung). Die patientenindividuelle Abwägung therapiespezifischer Vor- und Nachteile einer feldgerichteten Therapie ist herausfordernd. Fragestellung Ziel der vorliegenden Arbeit war die Entwicklung und Evaluierung patientenorientierter Entscheidungskriterien, die sich für die pragmatische Einordnung einer AK-Feldtherapie im Behandlungsalltag bei Patienten mit besonderer Prädisposition zur Feldkanzerisierung eignen (Patiententyp 1 bis 3). Material und Methoden Die Entwicklung der Entscheidungskriterien und der Patiententypologie erfolgte im Rahmen eines nominalen bzw. strukturierten Multi-level-Gruppenprozesses. Anhand der patientenrelevanten Entscheidungskriterien, der verfügbaren Evidenz aus klinischen Studien und entlang der Patiententypologie wurde ein Bewertungsalgorithmus etabliert, und feldgerichtete AK-Therapieoptionen wurden systematisch evaluiert. Ergebnisse Als patientenrelevante Kriterien für die Therapieentscheidung wurden u. a. Effektivität, Sicherheit, Praktikabilität der Therapie, Adhärenz, Kosmetik, Patientenpräferenz und Komorbiditäten identifiziert und näher spezifiziert. In Bezug auf diese Entscheidungskriterien und Patiententypen, bei denen eine Feldtherapie vorrangig indiziert ist, erfüllte die photodynamische Therapie mit Tageslicht das therapiebezogene Anforderungsprofil in besonderem Maße. Schlussfolgerung Die Definition von patientenrelevanten und therapiebezogenen Entscheidungskriterien in der AK-Feldtherapie erlaubt eine strukturierte und gleichzeitig praxisorientierte Herangehensweise, um spezifische Therapieoptionen einzuordnen und individuelle Therapieentscheidungen herzuleiten.
Collapse
Affiliation(s)
- W G Philipp-Dormston
- Fakultät für Gesundheit, Universität Witten/Herdecke, Witten, Deutschland. .,Hautzentrum Köln, Klinik Links vom Rhein, Schillingsrotter Str. 39-41, 50996, Köln, Deutschland.
| | - R Aschoff
- Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland
| | - T von Braunmühl
- Praxis für Dermatologie und Allergologie im Isarklinikum München, München, Deutschland
| | - T Eigentler
- Zentrum für Dermatologische Onkologie, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - T Haalck
- Fachbereich Dermatologie, Ambulanzzentrum des UKE GmbH - Medizinisches Versorgungszentrum (MVZ) des Universitätsklinikums Hamburg-Eppendorf (UKE), Hamburg, Deutschland
| | - K-M Thoms
- Hautkrebszentrum der UMG/Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Göttingen (UMG), Göttingen, Deutschland
| |
Collapse
|
11
|
Gutzmer R, Eigentler T, Mohr P, Weichenthal M, Dücker P, Gebhardt C, Göppner D, Haferkamp S, Kähler K, Meier F, Pföhler C, Satzger I, Sickmann T, Sindrilaru A, Terheyden P, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D. 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
12
|
Ascierto P, Robert C, Lewis K, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira R, Eigentler T, Rutkowski P, Demidov L, Manikhas GM, McNally V, Forbes H, Shah K, Yan Y, McArthur G. 1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Gellrich FF, Hüning S, Beissert S, Eigentler T, Stockfleth E, Gutzmer R, Meier F. Medical treatment of advanced cutaneous squamous-cell carcinoma. J Eur Acad Dermatol Venereol 2020; 33 Suppl 8:38-43. [PMID: 31833610 DOI: 10.1111/jdv.16024] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 10/21/2019] [Indexed: 01/23/2023]
Abstract
Considering the rising incidence, cutaneous squamous-cell carcinoma (cSCC) has a high clinical relevance. In patients with localized cSCC, complete surgical resection is indicated. Radiotherapy should be performed in patients with non-resectable tumours or in patients who are not suitable for surgery. Systemic therapy is reserved for cSCC that are neither surgically nor radiotherapeutically curable due to their extensive local spread and/or local or distant metastasis. In the absence of prospective randomized phase 3 trials to evaluate and compare the efficacy and safety of chemotherapeutics, epidermal growth factor receptor (EGFR) inhibitors and anti-PD-1 antibodies, no final recommendation for systemic therapy can be given for patients with locally advanced or metastatic cSCC. Anti-PD-1 antibodies currently show promising results with response rates of up to 50% in both locally advanced and metastatic cSCC. Anti-PD-1 antibodies appear to achieve higher response rates compared with EGFR inhibitors, and the duration of response appears to be superior to both chemotherapy and EGFR inhibitors. Compared with chemotherapy, the side effect profile of anti-PD-1 antibodies appears to be favourable. Altogether, PD-1 inhibitors are expected to become the new standard of care for patients with locally advanced and metastatic cSCC. Currently, placebo-controlled clinical trials are investigating the adjuvant use of cemiplimab and pembrolizumab in patients undergoing resection and radiotherapy of high-risk cSCC. Patients not eligible for anti-PD-1 treatment, e.g. in organ transplant recipients, or in patients refractory to anti-PD-1 may be offered EGFR inhibitors and/or chemotherapies. Chemotherapies appear to be superior to EGFR inhibitors in terms of response rates, whereas EGFR inhibitors have a more favourable toxicity profile. EGFR inhibitors are therefore more suitable for multimorbid and/or frail elderly patients. By combining EGFR inhibitors with local therapy such as surgery or radiotherapy, response rates and duration of response may be improved.
Collapse
Affiliation(s)
- F F Gellrich
- Dermatology, National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Dresden, Germany
| | - S Hüning
- Dermatology, Klinikum Dortmund gGmbH, Dortmund, Germany
| | - S Beissert
- Dermatology, National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Dresden, Germany
| | - T Eigentler
- Dermatology, Universitätsklinikum Tübingen, Tübingen, Germany
| | - E Stockfleth
- Dermatology and Allergology, University of Bochum, Bochum, Germany
| | - R Gutzmer
- Department of Dermatology and Allergy, Skin Cancer Center, Hannover Medical School, Hannover, Germany
| | - F Meier
- Dermatology, National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Dresden, Germany
| |
Collapse
|
14
|
Rischin D, Lim A, Schmults C, Khushalani N, Hughes B, Schadendorf D, Dunn L, Chang A, Hauschild A, Ulrich C, Eigentler T, Migden M, Pavlick A, Geiger J, Stankevich E, Li S, Lowy I, Fury M, Guminski A. Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Hassel J, Berking C, Eigentler T, Gutzmer R, Ascierto P, Schilling B, Hermann F, Bartz R, Schadendorf D. Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.058] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Knispel S, Gassenmaier M, Menzies A, Loquai C, Johnson D, Franklin C, Gutzmer R, Hassel J, Weishaupt C, Eigentler T, Schummer P, Kiecker F, Owen C, Schmidgen M, Kähler K, Cann C, Niebel D, Mohr P, Schadendorf D, Zimmer L. Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, Weide B, Ochsenreither S, Gutzmer R, Becker J, Kiecker F, Funkner F, Heidenreich R, Kays SK, Klinkhardt U, Gnad-Vogt U, Scheel B, Schönborn-Kellenberger O, Seibel T. A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Berking C, Livingstone E, Weichenthal M, Leiter U, Wittmann K, Eigentler T, Mohr P, Kiecker F, Loquai C, Debus D, Gutzmer R. Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz255.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
19
|
Schadendorf D, Hassel J, Fluck M, Eigentler T, Loquai C, Berneburg M, Gutzmer R, Meier F, Mohr P, Hauschild A, Becker J, Menzer C, Kiecker F, Dippel E, Simon JC, Conrad B, Garbe C, Körner S, Livingstone E, Zimmer L. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.064] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies A, Eigentler T, Ascierto P, Smylie M, Ajaz M, Svane IM, Gonzalez R, Rollin L, Saci A, Grigoryeva E, Pigozzo J. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.057] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Forschner A, Keim U, Hofmann M, Spänkuch I, Lomberg D, Weide B, Tampouri I, Eigentler T, Fink C, Garbe C, Haenssle HA. Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions. Br J Dermatol 2018; 179:478-485. [PMID: 29569229 DOI: 10.1111/bjd.16565] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/11/2018] [Indexed: 01/13/2023]
Abstract
BACKGROUND Early detection is a key factor in improving survival from melanoma. Today, the clinical diagnosis of cutaneous melanoma is based mostly on visual inspection and dermoscopy. Preclinical studies in freshly excised or paraffin-embedded tissue have shown that the melanin fluorescence spectra after stepwise two-photon excitation, a process termed dermatofluoroscopy, differ between cutaneous melanoma and melanocytic naevi. However, confirmation from a larger prospective clinical study is lacking. OBJECTIVES The primary end point of this study was to determine the diagnostic accuracy of dermatofluoroscopy in melanoma detection. Secondary end points included the collection of data for improving the computer algorithm that classifies skin lesions based on melanin fluorescence and the assessment of safety aspects. METHODS This was a prospective, blinded, multicentre clinical study in patients with pigmented skin lesions (PSLs) indicated for excision either to rule out or to confirm cutaneous melanoma. All included lesions underwent dermoscopy and dermatofluoroscopy in vivo before lesions were excised and subjected to histopathological examination. RESULTS In total, 369 patients and 476 PSLs were included in the final analysis. In 101 of 476 lesions (21·2%) histopathology revealed melanoma. The observed sensitivity of dermatofluoroscopy was 89·1% (90 of 101 melanomas identified), with an observed specificity of 44·8%. The positive and negative predictive values were 30·3% and 93·9%, respectively. No adverse events occurred. CONCLUSIONS Dermatofluoroscopy is a safe and accurate diagnostic method to aid physicians in diagnosing cutaneous melanoma. Limitations arise from largely amelanotic or regressing lesions lacking sufficient melanin fluorescence.
Collapse
Affiliation(s)
- A Forschner
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - U Keim
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - M Hofmann
- University Department of Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - I Spänkuch
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - D Lomberg
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - B Weide
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - I Tampouri
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - T Eigentler
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - C Fink
- Department of Dermatology, University of Heidelberg, Im Neuenheimer Feld 440,, 69120, Heidelberg, Germany
| | - C Garbe
- Centre of Dermatooncology, Department of Dermatology, Eberhard-Karls-University, Tübingen, Germany
| | - H A Haenssle
- Department of Dermatology, University of Heidelberg, Im Neuenheimer Feld 440,, 69120, Heidelberg, Germany
| |
Collapse
|
22
|
Eigentler T, Leiter U. Aktuelle Systemtherapie des metastasierten malignen Melanoms. Akt Dermatol 2017. [DOI: 10.1055/s-0043-104849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- T. Eigentler
- Zentrum für Dermato-Onkologie der Universitäts-Hautklinik, Eberhard Karls Universität Tübingen
| | - U. Leiter
- Zentrum für Dermato-Onkologie der Universitäts-Hautklinik, Eberhard Karls Universität Tübingen
| |
Collapse
|
23
|
Zinsser D, Othman A, Eigentler T, Garbe C, Nikolaou K, Klumpp B. Dosisreduziertes CT zum Staging von Melanompatienten – Evaluation von Strahlendosis und diagnostischer Genauigkeit im Vergleich zum Standarddosis-CT. ROFO-FORTSCHR RONTG 2017. [DOI: 10.1055/s-0037-1600428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- D Zinsser
- Universitätsklinikum Tübingen, Diagnostische und Interventionelle Radiologie, Tübingen
| | - A Othman
- Universitätsklinikum Tübingen, Diagnostische und Interventionelle Radiologie, Tübingen
| | - T Eigentler
- Universitätsklinikum Tübingen, Universitäts-Hautklinik, Tübingen
| | - C Garbe
- Universitätsklinikum Tübingen, Universitäts-Hautklinik, Tübingen
| | - K Nikolaou
- Universitätsklinikum Tübingen, Diagnostische und Interventionelle Radiologie, Tübingen
| | - B Klumpp
- Universitätsklinikum Tübingen, Diagnostische und Interventionelle Radiologie, Tübingen
| |
Collapse
|
24
|
Schneider LA, Eigentler T, Crisan D, Neckermann V, Kampilafkos P, Sindrilaru A, Scharffetter-Kochanek K, Treiber N. Erkennungshäufigkeit und Zeitraster bei der Erkennung von Melanomen durch den Patienten selbst und was bedeutet das für den Chirurgen? Akt Dermatol 2015. [DOI: 10.1055/s-0035-1558619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Schüle SC, Eigentler T, Pfannenberg C. [Multiple enlarged metabolically active lymph nodes in 18F-FDG PET/CT after anti-CTLA-4 antibody therapy in metastatic melanoma - disease progression or immunologically induced side effect?]. ROFO-FORTSCHR RONTG 2015; 187:1036-7. [PMID: 26062178 DOI: 10.1055/s-0034-1399672] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Schüle SC, Garbe C, Eigentler T, Claussen CD, la Fougère C, Pfannenberg C. Vergleich von CT und 18F-FDG-PET/CT im Rahmen des Therapiemanagements von Patienten mit metastasiertem malignen Melanom – Analyse des Outcome nach 5 Jahren Follow up. ROFO-FORTSCHR RONTG 2014. [DOI: 10.1055/s-0034-1372795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
27
|
Klumpp B, Schabel C, Eigentler T, Garbe C, Claussen C, Thomas C. Jodselektive Bildgebung mit Dual Energy Computertomografie zur Verlaufsbeobachtung von Melanommetastasen unter Systemtherapie. ROFO-FORTSCHR RONTG 2014. [DOI: 10.1055/s-0034-1372797] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-8. [PMID: 20372154 PMCID: PMC2856002 DOI: 10.1038/sj.bjc.6605622] [Citation(s) in RCA: 118] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background: This retrospective study aimed to identify prognostic factors in patients with brain metastases from cutaneous melanoma. Methods: In all, 265 patients under regular screening according to valid national surveillance guidelines were included in the study. Kaplan–Meier analyses were performed to estimate and to compare overall survival. Cox modeling was used to identify independent determinants of the overall survival, which were used in explorative classification and regression tree analysis to define meaningful prognostic groups. Results: In total, 55.5% of our patients presented with two or less brain metastases, 82.6% had concurrent extracranial metastasis and 64% were asymptomatic and diagnosed during surveillance scans. In all, 36.7% were candidates for local treatment (neurosurgery or stereotactic radiosurgery (SRS)). The median overall survival of the entire collective was 5.0 months (95% confidence interval: 4.3–5.7). Favourable independent prognostic factors were: normal pre-treatment level of serum lactate dehydrogenase (P<0.001), administered therapy (neurosurgery or SRS vs other, P=0.002), number of brain metastases (single vs multiple, P=0.032) and presence of bone metastasis (false vs true, P=0.044). Three prognostic groups with significantly different overall survival were identified. Candidates for local treatment (group I) had the longer median survival (9 months). Remaining patients could be further classified in two groups on the basis of serum lactate dehydrogenase. Conclusion: Applied treatment and serum lactate dehydrogenase levels were independent predictors of survival of patients with brain metastases from cutaneous melanoma. Patients receiving local therapy have overall survival comparable with general stage IV melanoma patients.
Collapse
Affiliation(s)
- M Staudt
- Department of Dermatology, Eberhard-Karls-University, Tuebingen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Eigentler T, Garbe C. Aktuelle Therapie des malignen Melanoms. Akt Dermatol 2008. [DOI: 10.1055/s-2008-1077574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Hauschild A, Volkenandt M, Tilgen W, Linse R, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Weichenthal M. Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Hauschild A, Trefzer U, Garbe C, Kaehler K, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schadendorf D. A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8044] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8044 Background: The acetylation of histones is a key component of gene regulation, which plays an important role in tumor initiation and progression. MS-275, an inhibitor of the benzamide series, is a synthetic orally available inhibitor of HDACs which showed anti-tumor activity in 3 phase 1 trials. Methods: A phase II, multicenter, randomized, parallel-group study of oral MS-275 evaluated the efficacy and toxicity in patients with non-resectable metastatic melanoma. Patients should have received at least one, but not more than two previous systemic therapies (chemo- and/or immunotherapy) for stage IV melanoma. Patients were stratified to receive either 3 mg MS-275 biweekly (days 1+15 of a 4-week cycle) or 7 mg MS-275 weekly (days 1+8+15 of a 4-week cycle) until disease progression or unacceptable toxicity. Study endpoints were the assessment of tumor response and toxicity. Results: A total of 28 patients have been randomized equally to the two dosing groups. Patients were classified as belonging to AJCC stage IVa (n=0), IVb (n=9; 32%), and IVc (n=19; 68%). In general, MS-275 was very well tolerated. No treatment-related SAEs have been observed. Most frequently reported side effects were nausea (CTC Grade 1+2, 32%) hypophosphatemia (CTC Grade 1–3, 29%), and diarrhea (CTC Grade 1+2, 18%). Stable diseases lasting from 8 wks to more than 48 wks have been observed in 4 pts (29%) in the 3 mg and 3 pts (21%) in the 7 mg dose group. Stabilizations occurred in these metastatic localizations: skin, peripheral and visceral lymph nodes, lung and bone, respectively. However, objective tumor responses were not observed. Conclusions: The results suggest that MS-275 is well tolerated and shows long-lasting tumor stabilizations in patients with pre-treated metastatic melanoma. The failure of objective tumor responses in the single-agent treatment with MS-275 warrants further evaluation also in combinational settings. [Table: see text]
Collapse
Affiliation(s)
- A. Hauschild
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - U. Trefzer
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - C. Garbe
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - K. Kaehler
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - S. Ugurel
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - F. Kiecker
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - T. Eigentler
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - H. Krissel
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| | - D. Schadendorf
- University of Kiel, Kiel, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; University of Tuebingen, Tuebingen, Germany; University Hospital, Mannheim, Germany; Schering, AG, Berlin, Germany
| |
Collapse
|